Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 310.4
(-0.06%)
SEK 310.4
(-0.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.65 Billion SEK | 22.11% |
| 2022 | 3.81 Billion SEK | 2.14% |
| 2021 | 3.73 Billion SEK | -22.52% |
| 2020 | 4.81 Billion SEK | 6.29% |
| 2019 | 4.53 Billion SEK | 45.2% |
| 2018 | 3.12 Billion SEK | 95.08% |
| 2017 | 1.6 Billion SEK | 41.24% |
| 2016 | 1.13 Billion SEK | 675.88% |
| 2015 | 146.04 Million SEK | 144.94% |
| 2014 | -324.97 Million SEK | -388.45% |
| 2013 | -66.53 Million SEK | -21.84% |
| 2012 | -54.6 Million SEK | 82.86% |
| 2011 | -318.61 Million SEK | -3023.69% |
| 2010 | -10.2 Million SEK | -163.06% |
| 2009 | 16.17 Million SEK | -52.84% |
| 2008 | 34.29 Million SEK | -37.77% |
| 2007 | 55.11 Million SEK | 0.97% |
| 2006 | 54.58 Million SEK | -79.97% |
| 2005 | 272.56 Million SEK | 374.64% |
| 2004 | 57.42 Million SEK | -4.03% |
| 2003 | 59.83 Million SEK | 35.64% |
| 2002 | 44.11 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.31 Billion SEK | -18.09% |
| 2024 Q2 | 640 Million SEK | -51.26% |
| 2024 Q3 | 2.03 Billion SEK | 218.44% |
| 2023 Q2 | 413 Million SEK | -72.37% |
| 2023 Q4 | 1.6 Billion SEK | 193.05% |
| 2023 Q3 | 547 Million SEK | 32.45% |
| 2023 Q1 | 1.49 Billion SEK | -21.97% |
| 2023 FY | 4.65 Billion SEK | 22.11% |
| 2022 Q3 | 699 Million SEK | 116.41% |
| 2022 Q4 | 1.91 Billion SEK | 174.11% |
| 2022 Q2 | 323 Million SEK | -58.38% |
| 2022 FY | 3.81 Billion SEK | 2.14% |
| 2022 Q1 | 776 Million SEK | -49.11% |
| 2021 Q1 | 1.03 Billion SEK | -51.13% |
| 2021 Q4 | 1.52 Billion SEK | 115.4% |
| 2021 Q3 | 708 Million SEK | 51.61% |
| 2021 Q2 | 467 Million SEK | -54.84% |
| 2021 FY | 3.73 Billion SEK | -22.52% |
| 2020 Q3 | 464 Million SEK | -14.23% |
| 2020 Q1 | 1.69 Billion SEK | -9.39% |
| 2020 Q2 | 541 Million SEK | -68.14% |
| 2020 FY | 4.81 Billion SEK | 6.29% |
| 2020 Q4 | 2.11 Billion SEK | 356.03% |
| 2019 Q3 | 754 Million SEK | 11.37% |
| 2019 Q4 | 1.87 Billion SEK | 148.54% |
| 2019 FY | 4.53 Billion SEK | 45.2% |
| 2019 Q1 | 1.22 Billion SEK | 53.0% |
| 2019 Q2 | 677 Million SEK | -44.82% |
| 2018 FY | 3.12 Billion SEK | 95.08% |
| 2018 Q3 | 820 Million SEK | -2.5% |
| 2018 Q2 | 841 Million SEK | 27.42% |
| 2018 Q4 | 801.96 Million SEK | -2.2% |
| 2018 Q1 | 660 Million SEK | 29.83% |
| 2017 FY | 1.6 Billion SEK | 41.24% |
| 2017 Q4 | 508.36 Million SEK | 19.33% |
| 2017 Q3 | 426 Million SEK | 11.81% |
| 2017 Q2 | 381 Million SEK | 34.15% |
| 2017 Q1 | 284 Million SEK | 186.54% |
| 2016 FY | 1.13 Billion SEK | 675.88% |
| 2016 Q3 | 171 Million SEK | -62.25% |
| 2016 Q1 | 410 Million SEK | 2305.68% |
| 2016 Q2 | 453 Million SEK | 10.49% |
| 2016 Q4 | 99.11 Million SEK | -42.04% |
| 2015 Q3 | 25 Million SEK | 733.33% |
| 2015 FY | 146.04 Million SEK | 144.94% |
| 2015 Q1 | 102 Million SEK | 412.17% |
| 2015 Q4 | 17.04 Million SEK | -31.83% |
| 2015 Q2 | 3 Million SEK | -97.06% |
| 2014 Q4 | -32.67 Million SEK | -165.74% |
| 2014 FY | -324.97 Million SEK | -388.45% |
| 2014 Q3 | 49.7 Million SEK | 210.63% |
| 2014 Q2 | 16 Million SEK | 104.47% |
| 2014 Q1 | -358 Million SEK | -7158.72% |
| 2013 Q2 | -31.9 Million SEK | -838.24% |
| 2013 Q1 | -3.4 Million SEK | 98.24% |
| 2013 Q4 | -4.93 Million SEK | 81.25% |
| 2013 FY | -66.53 Million SEK | -21.84% |
| 2013 Q3 | -26.3 Million SEK | 17.55% |
| 2012 Q3 | -34.7 Million SEK | 50.29% |
| 2012 Q4 | -192.8 Million SEK | -455.64% |
| 2012 FY | -54.6 Million SEK | 82.86% |
| 2012 Q1 | 242.6 Million SEK | 174.03% |
| 2012 Q2 | -69.8 Million SEK | -128.77% |
| 2011 Q2 | 127.3 Million SEK | 299.84% |
| 2011 Q3 | -54.4 Million SEK | -142.73% |
| 2011 FY | -318.61 Million SEK | -3023.69% |
| 2011 Q4 | -327.71 Million SEK | -502.42% |
| 2011 Q1 | -63.7 Million SEK | -368.78% |
| 2010 FY | -10.2 Million SEK | -163.06% |
| 2010 Q1 | -43.4 Million SEK | -184.48% |
| 2010 Q2 | 4.5 Million SEK | 110.37% |
| 2010 Q4 | 23.7 Million SEK | 374.0% |
| 2010 Q3 | 5 Million SEK | 11.11% |
| 2009 Q3 | -34.1 Million SEK | -160.31% |
| 2009 Q1 | 12 Million SEK | 0.0% |
| 2009 Q4 | 51.37 Million SEK | 250.66% |
| 2009 FY | 16.17 Million SEK | -52.84% |
| 2009 Q2 | -13.1 Million SEK | -209.17% |
| 2008 FY | 34.29 Million SEK | -37.77% |
| 2007 FY | 55.11 Million SEK | 0.97% |
| 2006 FY | 54.58 Million SEK | -79.97% |
| 2005 FY | 272.56 Million SEK | 374.64% |
| 2004 FY | 57.42 Million SEK | -4.03% |
| 2003 FY | 59.83 Million SEK | 35.64% |
| 2002 FY | 44.11 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | 35242.275% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 12268.731% |
| BioGaia AB (publ) | 440.9 Million SEK | -956.0% |
| Enzymatica AB (publ) | -48.06 Million SEK | 9787.487% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 11228.639% |
| Gabather AB (publ) | -9.47 Million SEK | 49245.028% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | 31816.621% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 17053.72% |
| Nanexa AB (publ) | -76.62 Million SEK | 6176.346% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | 33172.88% |
| ODI Pharma AB | -1.34 Million SEK | 347137.954% |
| Orexo AB (publ) | -109.5 Million SEK | 4352.055% |
| Probi AB (publ) | 11.32 Million SEK | -41030.742% |
| Swedencare AB (publ) | 173.2 Million SEK | -2588.222% |
| Toleranzia AB | -7.89 Million SEK | 59103.929% |
| Vivesto AB | -356.71 Million SEK | 1405.229% |